semaglutide cancer study GLP-1s appear to cut risk. Researchers are asking why and how : NPR A 30% Risk Reduction Sounds

In simple terms, this allows it to remain bioactive for much longer than standard IGF-1, making it a powerful and consistent compound for research into cellular growth and proliferation

Research 2

Keep fat moderate Fat is not bad

For example, in the REWIND trial dulaglutide at the commonly used dose of 1.5 mg in people with T2D was associated with an average increase of 1.9 bpm over 5 years of treatment exposure [4]

5 Unlimited telehealth check-ins included Monthly follow-ups, dosage adjustments, and provider access are all included no extra fees

Beta-glucan can help a person feel full for longer, as its digests slowly, contributing to weight loss